Immunotherapy advancements show promise in treating colorectal and melanoma cancers

Recent clinical studies have demonstrated significant progress in cancer treatment through immunotherapy. Research conducted by the Antoni van Leeuwenhoek Institute in the Netherlands, published in The Lancet, focused on colorectal cancer. In a study of 111 patients, immunotherapy was used as a supplement to traditional methods, resulting in no recorded cancer recurrences within five years of treatment completion.

In a separate study involving 1,137 adult patients with melanoma, an experimental personalized mRNA vaccine called Intismeran was administered alongside pembrolizumab. The results indicated a 42 percent reduction in the risk of melanoma recurrence or death compared to those receiving immunotherapy alone. Additionally, the study noted a 38 percent reduction in the risk of cancer spread. The Intismeran vaccine is tailored to the specific genetic information of an individual patient's tumor to prime the immune system to recognize and combat cancer cells.